Healthcare
SI-BONE, Inc.(SIBN)
Live Price
Offline$15.42
+1.85% today
1Y Change
-6.66%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $580.00M
- Revenue Growth
- +20.2%
- EPS Growth
- +41.3%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
SI-BONE, Inc. (SIBN) is a Healthcare stock with a market cap of $580.00M and listed on NASDAQ. The stock last traded around $15.42 and down 6.7% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +20.2%, EPS growth of +41.3%, a dividend yield of 0.0%. What stands out right now is revenue +20.2%, EPS +41.3%, free cash flow +60.3% with operating margin -11.1% and ROIC -10.4%. Valuation is more restrained than many high-expectation growth names at price/sales 2.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SIBN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+20.2% vs +7.6% peer median
Operating Margin
Below sector median
-11.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 4, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +20.2% and EPS at +41.3%, with operating margin around -11.1%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 2, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.6% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 4, 2026 | โ | +1.5% | -13.0% | +4.9% |
2026 Feb 23, 2026 | +69.2% | -2.1% | +0.5% | -16.8% |
2025 Nov 10, 2025 | +31.3% | +16.2% | +14.3% | +21.2% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SIBN
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SIBN Max Drawdown
-45.75%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SIBN and SPY.
Company Overview
SI-BONE, Inc.
NASDAQ Global Market
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
- Leadership
- Laura A. Francis
- IPO Date
- Oct 17, 2018
- Employees
- 349
- Street Address
- 471 El Camino Real
- Mailing
- Santa Clara, CA, 95050
- Region
- Santa Clara, CA, US
- Reporting Currency
- USD
- Investor Line
- 408 207 0700
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 2.9
- Price/Book
- 3.2
Growth
- Revenue
- +20.2%
- EPS
- +41.3%
- Free Cash Flow
- +60.3%
Profitability
- Gross Margin
- 79.6%
- Operating Margin
- -11.1%
- Net Margin
- -9.4%
- ROE
- -11.0%
- ROIC
- -10.4%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 8.55
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.